Advanced Prostate Cancer Articles & Analysis
26 news found
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. ...
” About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients ...
About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a ...
In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting. About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing ...
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
“For those diagnosed with advanced prostate cancer, it is crucial to find a treatment that is not only effective but allows them to safely preserve their quality of life,” said Bertrand Tombal, M.D., Ph.D., Professor of Urology, Université catholique de Louvain (UCL), Cliniques universitaires, Saint-Luc, Brussels, Belgium. ...
ByBayer AG
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating ...
About Vivesto Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a ...
” About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients ...
Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. Dr. Pankaj Jain at Arizona Urology said, “With our goal to offer the most advanced prostate cancer diagnostics ...
Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
Profound subsequently signed the first site agreement for a TULSA-PRO® system interfaced with a GE scanner with Boston’s renowned Brigham and Women's Hospital. “Prostate cancer is the second most common cancer diagnosis and a leading cause of mortality in men worldwide1,” explained Anja Brau, General Manager of MR Clinical ...
As the recognized leader in PET prostate cancer diagnostic imaging, we are actively progressing our comprehensive prostate cancer portfolio, which includes 18F-fluciclovine and our investigational rhPSMA technology platform. ...
Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 ...
TORONTO, CANADA – Focal Healthcare, known globally as a leading innovator of image-guided prostate cancer technology, is diversifying their product line by developing an AI-based 3D ultrasound imaging platform. ...
Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
“TULSA-PRO® is a customizable and incision-free prostate disease treatment system that minimizes the impact on men’s functional abilities and provides the highest quality of life after treatment. ...
The Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House was established in September 2009 by the AdMeTech Foundation, a non-profit organization. This event resulted in the rapidly growing recognition of prostate cancer as a public health priority and support for increased research funding for the ...